Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)

NCT05698017 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple System Atrophy
MSA - Multiple System Atrophy

Interventions

BIOLOGICAL: hOMSC300

Sponsor

Cytora Ltd.